Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/08/2007WO2007027230A2 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
03/08/2007WO2007027187A1 Anti-inflammatory compositions and methods of use
03/08/2007WO2007027178A2 Lyophilized platelet rich plasma for the use in wound healing and bone or tissue grafts or repair
03/08/2007WO2007027134A1 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS
03/08/2007WO2007027133A1 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS
03/08/2007WO2007027118A1 Dermatological composition
03/08/2007WO2007027077A1 Skin-care preparations containing mupirocin and betamethasone dipropionate
03/08/2007WO2007026996A1 Glucosamine and derivatives thereof useful as tg inhibitors
03/08/2007WO2007026966A1 Thiomorpholine compound and process for preparing the same
03/08/2007WO2007026962A1 Phenylene derivative
03/08/2007WO2007026960A1 Use of mocs3 gene for therapeutic or diagnostic purposes
03/08/2007WO2007026959A2 Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders
03/08/2007WO2007026950A1 Pyridazinone derivatives used for the treatment of pain
03/08/2007WO2007026928A1 Therapeutic agent for neuropathic pain
03/08/2007WO2007026916A1 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
03/08/2007WO2007026897A1 Oral composition for prevention or treatment of skin blemishes or freckles and food
03/08/2007WO2007026869A1 Antitumor agent
03/08/2007WO2007026824A1 Oligonucleotide analogs
03/08/2007WO2007026820A1 Utilization of hypertension/hypercardia-preventing effect of d-allose
03/08/2007WO2007026771A1 Injection for intravenous drip
03/08/2007WO2007026761A1 Thiazole derivative
03/08/2007WO2007026742A1 Colonic delivery-type therapeutic agent for inflammatory bowel disease
03/08/2007WO2007026737A1 Prophylactic and/or therapeutic method for rheumatoid arthritis
03/08/2007WO2007026725A2 Drug, drug gudance system, magnetic detection system, and drug design method
03/08/2007WO2007026720A1 Ring-fused pyrazole derivative
03/08/2007WO2007026664A1 Sulfonamide compound
03/08/2007WO2007026651A1 Therapeutic agent for hypertension
03/08/2007WO2007026630A1 Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
03/08/2007WO2007026533A1 Soluble tablet containing nanosilicon particles and process for production thereof
03/08/2007WO2007026358A2 Compositons comprising phosphatidic acid for treatment of eosinophilia and related disorders
03/08/2007WO2007026246A2 Synapse-specific proteins in glomeruli
03/08/2007WO2007026240A1 Sunscreen and cosmetic compositions for prophylaxis or treatment of skin cancers
03/08/2007WO2007026224A2 5-ht1b antagonist composition for depression, anxiety and cognition
03/08/2007WO2007026219A2 Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
03/08/2007WO2007026218A2 Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
03/08/2007WO2007026215A1 Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
03/08/2007WO2007026203A1 A pharmaceutical composition comprising mahanine useful for the treatment of prostate cancer
03/08/2007WO2007026157A1 Atm inhibitor
03/08/2007WO2007026156A1 Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
03/08/2007WO2007026125A2 Anti-viral topical gel formulations containing a diuretic such as furosemide and/or a cardiac glycoside such as digoxin
03/08/2007WO2007026124A2 Transdermal delivery means of a diuretic agent and/or cardiac glycoside agent
03/08/2007WO2007026104A1 Pyrrolopyridine derivatives and use of same as ppar receptor modulators
03/08/2007WO2007026097A1 Novel indole compounds
03/08/2007WO2007026071A1 Use of dha in the form of phospholipids for the preparation of a composition that is intended for the treatment of respiratory failure
03/08/2007WO2007026027A1 Novel ansamycin derivatives
03/08/2007WO2007026024A2 Benzodiazepines as hcv inhibitors
03/08/2007WO2007026009A1 Novel tyrosinase-specific antigenic oligonucleotides as depigmenting agents
03/08/2007WO2007025999A1 Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus
03/08/2007WO2007025994A2 Use of at least one 2-alkyl furan, as depigmenting or lightening active principle
03/08/2007WO2007025991A2 Treatment of optic neuritis
03/08/2007WO2007025978A1 Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/08/2007WO2007025949A1 Novel cycloalkane carboxamides as factor xa inhibitors
03/08/2007WO2007025940A1 Substituted biaryls and their use as factor xa inhibitors
03/08/2007WO2007025938A1 Non-steroidal compounds useful as glucocorticoid receptor modulators
03/08/2007WO2007025925A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007WO2007025901A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007WO2007025900A1 Diaminopyrimidines as p2x3 and p3x2/3 modulators
03/08/2007WO2007025899A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007WO2007025892A1 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
03/08/2007WO2007025780A2 Aldosterone receptor antagonists
03/08/2007WO2007025764A2 Pharmaceutical formulations for salts of monobasic acids comprising clopidogrel
03/08/2007WO2007025763A2 Highly cross-linked reagents for modifying biopharmaceuticals, production and use thereof
03/08/2007WO2007025751A1 Use of fused imidazole derivatives to mediate ccr3 related conditions
03/08/2007WO2007025721A1 Combined preparation of a thiazide diuretic and a loop diuretic
03/08/2007WO2007025718A1 Oxadiazole compounds as urokinase inhibitors
03/08/2007WO2007025695A1 Pharmaceutical composition comprising perindopril or its salts
03/08/2007WO2007025632A2 Nitrooxy derivatives op glucocorticoids
03/08/2007WO2007025604A1 4-chromenonyl-1,4-dihydropyridines and their use
03/08/2007WO2007025596A1 Pyrazolo [3 , 4-d] azepine derivatives as histamine h3 antagonists
03/08/2007WO2007025595A1 Use of soluble guanylate cyclase activators for treating reperfusion damage
03/08/2007WO2007025575A1 O-hydroxy- and o-amino benzamide derivatives as ikk2 inhibitors
03/08/2007WO2007025540A2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, the production thereof, and use of the same as medicaments
03/08/2007WO2007025534A1 Fredericamycin derivatives
03/08/2007WO2007025488A1 Method of production of fine-crystalline mixture containing non-steroid anti-inflammatory drug, fine-crystalline mixture obtainable by this method and solid pharmaceutical composition containing this mixture
03/08/2007WO2007025444A1 Carboxymethyl chitosan quaternary ammonium salt derivative and preparation method thereof
03/08/2007WO2007025431A1 Recombinant newcastle disease lasota attenuated vaccine strain expressing vp2 gene of infectious bursal disease virus
03/08/2007WO2007025383A1 Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist
03/08/2007WO2007025366A1 Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
03/08/2007WO2007025365A1 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
03/08/2007WO2007009691A3 Combination of substituted pyrazolines and anti -addictive agent
03/08/2007WO2007009686A3 Substituted pyrazoline compounds, their preparation and use as medicaments
03/08/2007WO2007009395A8 Schisandrin b preparation
03/08/2007WO2007009044A3 Inhibitors of egln3 activity for the treatment of neurodegenerative disorders
03/08/2007WO2007008317A3 Process for preparation of sertraline hydrochloride form i
03/08/2007WO2007005774A9 Novel derivatives of amino acids for treatment of obesity and related disorders
03/08/2007WO2007005668A3 Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
03/08/2007WO2007003962A3 Gpcr agonists
03/08/2007WO2007003425A3 Spray-drying process for producing a dry carnitine powder or granulate
03/08/2007WO2007002761A3 Micogel topical formulations
03/08/2007WO2007002293A3 Azaindazole compounds and methods of use
03/08/2007WO2007000001A3 Pleuromutilin salts with salicylic acid, azelaic acid, sebacic acid and diclofenac
03/08/2007WO2006138266A3 The preparation and use of compounds as aspartyl protease inhibitors
03/08/2007WO2006137009A3 Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as therapeutic and diagnostic agents
03/08/2007WO2006135915A3 Methods and compositions for treating degenerative bone disorders
03/08/2007WO2006134492A3 Acarbose methods and formulations for treating chronic constipation
03/08/2007WO2006134101A3 Use of pde1c and inhibitors thereof
03/08/2007WO2006133374A3 Methods for treating shock
03/08/2007WO2006128184A3 Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
03/08/2007WO2006128150A3 Crystalline solid forms of tigecycline and methods of preparing same
03/08/2007WO2006128070A3 Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist
1 ... 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 ... 7860